Evidence map›Paper›PMID 42255253›Full record

ArticleEuropean urology open science2026

Progression-free Survival Following Primary Staging with [

Karen M Buch-Olsen, Steinbjørn Hansen, Mie H Vilstrup, Mads H Poulsen, Paw C Holdgaard, Karsten E A Zieger, Jon T Asmussen, Jorun Holm, Kasper T Pedersen, Søren Hess and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Karen M Buch-OlsenDepartment of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
Steinbjørn HansenDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark.
Mie H VilstrupDepartment of Radiology and Nuclear Medicine, Esbjerg and Grindsted Hospitals, University of Southern Denmark, Esbjerg, Denmark.
Mads H PoulsenDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark.
Paw C HoldgaardDepartment of Nuclear Medicine, Lillebaelt Hospital - University Hospital of Southern Denmark, Vejle, Denmark.
Karsten E A ZiegerDepartment of Urology, Lillebaelt Hospital - University Hospital of Southern Denmark, Vejle, Denmark.
Jon T AsmussenDepartment of Radiology, Odense University Hospital, Odense, Denmark.
Jorun HolmDepartment of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
Kasper T PedersenDepartment of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
Søren HessDepartment of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
Søren S MadsenDepartment of Urology, Esbjerg and Grindsted Hospitals, University of Southern Denmark, Esbjerg, Denmark.
Matthias EiberDepartment of Nuclear Medicine, Technical University of Münich, Münich, Germany.
Oke GerkeDepartment of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
Malene G HildebrandtDepartment of Nuclear Medicine, Odense University Hospital, Odense, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To compare progression-free survival (PFS) in newly diagnosed prostate cancer (PCa) staged with prostate-specific membrane antigen prostate-specific membrane antigen 1007 ([ Design setting and participants: Patients with newly diagnosed PCa were enrolled in the multicenter, randomized controlled clinical Primary Staging of Prostate Cancer: A Randomized Controlled Trial Comparing [ 18 F]PSMA -1007 PET /CT to Conventional Imaging (PRISMA-PET) trial. Patients were staged with Na[ Results and limitations: We enrolled 385 patients from October 2021 to January 2025. The intention-to-treat principle was followed. Fewer patients were classified as nonmetastatic when staged with [ Conclusions: Staging with [

Indexed as

Clinical trialNa[18F]F-PET/CTProgression-free survivalProstate cancerPSMA-PET/CTRandomized controlled trialRCTStaging

Identifiers

PMID42255253
PMCPMC13233573

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.